Moderna: A Top COVID-19 Vaccine Player, but Is Its Valuation Justified? - Yahoo Finance

Images of death have been used as a scare tactic in public health campaigns for years.

There is compelling evidence that fear can change behavior, and there have been ethical arguments that using fear can be justified, particularly when threats are severe.

As public health professors with expertise in history and ethics, we have been open in some situations to using fear in ways that help individuals understand the gravity of a crisis without creating stigma.

Public health officials’ willingness to use it to help change behavior in public health campaigns has waxed and waned for more than a century.

From the late 19th century into the early 1920s, public health campaigns commonly sought to stir fear.

The key theme was using fear to control harm from others.

Library of Congress Following World War II, epidemiological data emerged as the foundation of public health, and use of fear fell out of favor.

But by the 1960s, health officials were trying to change behaviors related to smoking, eating and exercise, and they grappled with the limits of data and logic as tools to help the public.

Although there were concerns about using fear to manipulate people, leading ethicists began to argue that it could help people understand what was in their self-interest.

NYC Health Anti-tobacco campaigns were the first to show the devastating toll of smoking.

When it came to public health campaigns, human rights advocates argued, fear stigmatized and undermined the effort.

When obesity became a public health crisis, and youth smoking rates and vaping experimentation were sounding alarm bells, public health campaigns once again adopted fear to try to shatter complacency?

Health officials have faced armed protesters outside their offices and homes.

Reliance on fear for public health messaging now could further erode trust in public health officials and scientists at a critical juncture.

The nation desperately needs a strategy that can help break through pandemic denialism and through the politically charged environment, with its threatening and at times hysterical rhetoric that has created opposition to sound public health measures.

Instead, public health officials should boldly urge and, as they have during other crisis periods in the past, emphasize what has been sorely lacking: consistent, credible communication of the science at the national level.This article is republished from The Conversation, a nonprofit news site dedicated to sharing ideas from academic experts.

Read more:Video: Current rates of vaccine hesitancy in the US could mean a long road to normalcyCoronavirus vaccines: health experts identify ways to build public trustAmericans have unrealistic expectations for a COVID-19 vaccine Amy Lauren Fairchild received funding from the Greenwall Foundation and the National Science Foundation.

Pfizer Inc expects to deliver more than 13 million doses of its COVID-19 vaccine per week to the United States by the middle of March, more than doubling its shipments from early February, a top Pfizer executive said in prepared testimony ahead of a Tuesday congressional hearing.

Pfizer is on track to deliver 120 million doses of its two-dose regimen by the end of March, said John Young, Pfizer's chief business officer.

Pfizer is also prepared to provide a total of 300 million shots to the United States by the end of July and has raised global production expectations for 2021 to at least 2 billion doses, he said.

17, the company said in a release.

Meanwhile, Nio users drove a total of 30 million km in the same week, a 318% year-over-year increase, the company said in a WeChat post.

Nio Pilot, the company's autonomous driver assistance system, was used for more than 4 million km.

Related Link: Chairman Of Oil Giant Sinopec Visits Nio Battery Swap Station Geely Confirms EV Plans: Chinese automaker Geely Automobile Holdings Ltd (OTC: GELYF) confirmed it will form a separate all-electric vehicle company, cnEV Post said, citing an internal memo by Chairman Li Shufu.

Roger McIntyre as its Chairman and CEO, Champignon Brands (OTCQB: SHRMF) is a research-driven Psychedelics company specializing in breakthrough Ketamine treatment for depression and other mental health conditions.

Jim Cramer Slams Sundial as Cannabis Company Raises Over M Via Warrant Exchange Sundial Reported Friday That it Has Raised $89.1 Million Via a Warrant Exchange Sundial Growers (NASDAQ: SNDL) noted that holders of 98.33 million warrants to buy shares of the company will exercise for cash their warrants at prices of 80 cents and $1.10 for gross proceeds to the company.

READ FULL PSYCHEDELICS ETF ARTICLE 6.

Creso Pharma Signs $2.5 Million Distribution Deal, Enters New Lucrative Asian Markets Following a landmark Decision By the Country’s Government, Pakistan, With a Population of Over 216 million, Has Entered the Multi-Billion Dollar CBD Market Poised to capitalize on the massive new market opportunity, Creso Pharma (OTC: COPHF) has signed an exclusive distribution deal to bring the company’s innovative Hemp-derived CBD products into Pakistan and the Philippines.

The deal will also see Creso look at additional potential target markets, with a total addressable market of approximately 750 million people, which includes Cambodia, Afghanistan, Azerbaijan, Bangladesh, Georgia, the Maldives, Myanmar, Tajikistan, Turkmenistan, Uzbekistan, and Vietnam.

It also has the largest market cap among public U.S.

MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company The Acquisition Will Help Build a Full-Stack Digital Mental Health Platform for Psychedelic Medicines MindMed (OTCQB: MMEDF) announced that it will acquire HealthMode, a digital medicine and therapeutics startup that uses Artificial Intelligence (AI)-enabled digital measurement to increase the precision and speed of clinical research and patient monitoring.

Tilray Reports Profitable Q4, Says Aphria Merger is on Track Tilray Reported its First Profitable Quarterly Period on Wednesday, Ahead of its Planned Merger With Aphria The Nanaimo, B.C.-based cannabis producer said sharp increases in its adult-use and medical cannabis businesses led to it generating US$50.7 million in net revenue in the three-month period ended Dec.

Tilray (NASDAQ: TLRY) said it expects to close its blockbuster merger with Aphria (NYSE: APHA) in the second quarter of this year, which will make it the world’s largest cannabis company based on pro forma revenue.

READ FULL TLRY APHA ARTICLE Photo by Next Green Wave on Unsplash See more from BenzingaClick here for options trades from BenzingaCannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The WeekCannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week© 2021 Benzinga.com.

He’s now buying the FTSE 250 while selling the Eurostoxx Index.Here’s how the catch-up trade is playing out.Currency SupremacyAs the country delivers one of the fastest immunization programs in the world, the pound is one of the hottest trades in currency markets -- gaining around 2.5% against the dollar this year.Just last week, it breached the $1.40 threshold for the first time since 2018, while surging to the strongest versus the euro since the depths of the pandemic panic last March.The sterling rally may now have fresh legs, as the U.K.-euro area monetary path diverges.“Rates markets are starting to price in a future decoupling between the ECB and the BOE policy outlook, helped by the BOE effectively killing market speculation on negative rates,” said Valentin Marinov, head of G-10 currency research at Credit Agricole.The yield on benchmark U.K.

market, said Nicolas Trindade, a portfolio manager at Axa Investment Managers, which manages 758 billion pounds ($1.1 trillion).It’s a different story for investment-grade securities that are more prone to rate risk than their euro counterparts